These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26960405)

  • 41. Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered.
    Valeur KS; Holst H; Allegaert K
    Pharmaceut Med; 2018; 32(4):251-258. PubMed ID: 30174435
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mitigating unwanted amorphisation: A screening method for the selection of suitable excipients.
    Amharar Y; Curtin V; Gallagher KH; O'Siochru E; O'Connell P; Healy AM
    Eur J Pharm Sci; 2016 Jan; 81():181-8. PubMed ID: 26493586
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Magistral drugs in hospitalized newborns and children.
    Pereira AC; Miranda ES; Castilho SR; Futuro DO; Teixeira LA; Paula GR
    Rev Paul Pediatr; 2016 Dec; 34(4):403-407. PubMed ID: 27131897
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir.
    Vaithianathan S; Haidar SH; Zhang X; Jiang W; Avon C; Dowling TC; Shao C; Kane M; Hoag SW; Flasar MH; Ting TY; Polli JE
    J Pharm Sci; 2016 Feb; 105(2):996-1005. PubMed ID: 26375604
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The STEP (Safety and Toxicity of Excipients for Paediatrics) database: part 2 - the pilot version.
    Salunke S; Brandys B; Giacoia G; Tuleu C
    Int J Pharm; 2013 Nov; 457(1):310-22. PubMed ID: 24070789
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent advances in ocular drug delivery.
    Achouri D; Alhanout K; Piccerelle P; Andrieu V
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel insights into excipient effects on the biopharmaceutics of APIs from different BCS classes: Lactose in solid oral dosage forms.
    Kubbinga M; Moghani L; Langguth P
    Eur J Pharm Sci; 2014 Sep; 61():27-31. PubMed ID: 24732384
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk assessment of supply chain for pharmaceutical excipients with AHP-fuzzy comprehensive evaluation.
    Li M; Du Y; Wang Q; Sun C; Ling X; Yu B; Tu J; Xiong Y
    Drug Dev Ind Pharm; 2016 Apr; 42(4):676-684. PubMed ID: 26266963
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: impact on bioequivalence.
    García-Arieta A
    Eur J Pharm Sci; 2014 Dec; 65():89-97. PubMed ID: 25236823
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Excipients and additives: hidden hazards in drug products and in product substitution.
    Napke E; Stevens DG
    Can Med Assoc J; 1984 Dec; 131(12):1449-52. PubMed ID: 6498699
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The biological functions of lipid excipients and the implications for pharmaceutical products development.
    Wasan KM
    J Pharm Sci; 2009 Feb; 98(2):379-82. PubMed ID: 18484625
    [No Abstract]   [Full Text] [Related]  

  • 52. Biologic excipients: Importance of clinical awareness of inactive ingredients.
    Ionova Y; Wilson L
    PLoS One; 2020; 15(6):e0235076. PubMed ID: 32584876
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Miniaturized approach for excipient selection during the development of oral solid dosage form.
    Raijada D; Müllertz A; Cornett C; Munk T; Sonnergaard J; Rantanen J
    J Pharm Sci; 2014 Mar; 103(3):900-8. PubMed ID: 24436033
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers.
    James J; Crean B; Davies M; Toon R; Jinks P; Roberts CJ
    Int J Pharm; 2008 Sep; 361(1-2):209-21. PubMed ID: 18577435
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The activities of drug inactive ingredients on biological targets.
    Pottel J; Armstrong D; Zou L; Fekete A; Huang XP; Torosyan H; Bednarczyk D; Whitebread S; Bhhatarai B; Liang G; Jin H; Ghaemi SN; Slocum S; Lukacs KV; Irwin JJ; Berg EL; Giacomini KM; Roth BL; Shoichet BK; Urban L
    Science; 2020 Jul; 369(6502):403-413. PubMed ID: 32703874
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contact allergens in oral antihistamines.
    McEnery-Stonelake M; Silvestri DL
    Dermatitis; 2014; 25(2):83-8. PubMed ID: 24603514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immediate-type hypersensitivity reaction to Mannitol as drug excipient (E421): a case report.
    Calogiuri GF; Muratore L; Nettis E; Casto AM; Di Leo E; Vacca A
    Eur Ann Allergy Clin Immunol; 2015 May; 47(3):99-102. PubMed ID: 25951149
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral medicines for children in the European paediatric investigation plans.
    van Riet-Nales DA; Römkens EG; Saint-Raymond A; Kozarewicz P; Schobben AF; Egberts TC; Rademaker CM
    PLoS One; 2014; 9(6):e98348. PubMed ID: 24897509
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sorbitol content of selected oral liquids.
    Lutomski DM; Gora ML; Wright SM; Martin JE
    Ann Pharmacother; 1993 Mar; 27(3):269-74. PubMed ID: 8453159
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Investigation of the capacity of low glass transition temperature excipients to minimize amorphization of sulfadimidine on comilling.
    Curtin V; Amharar Y; Hu Y; Erxleben A; McArdle P; Caron V; Tajber L; Corrigan OI; Healy AM
    Mol Pharm; 2013 Jan; 10(1):386-96. PubMed ID: 23186332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.